Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Its their business plan read the ibox
Operational Plan
Month 1-2: Assembly of Team:
Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. -DONE
Month 1-4: Inlicensing of Intellectual Property:
The Company having already assessed over 20,000 issued patents and havingcompiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses onissued patents that have already passed preclinical studies but are not under clinical development. -DONE
Month 3-6: Interaction with Regulatory Agencies:
Regen intends to develop data packages for each of the technologies andinitiate interaction with Regulatory Agencies such as the FDA for initiation of trials.-DONE
Month 6-18: Clinical Implementation:
Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy. NEXT UP
Month 18-24: Exit:
It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.
Regen Biopharma, Inc. (PC) (RGBP)
http://ih.advfn.com/p.php?pid=nmona&article=69735998
Item 1.01 Entry Into A Material Definitive Agreement
On December 15, 2015 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services , pursuant to the following terms and conditions:
Regen and NCATS shall collaborate to screen for small molecule compounds that activate or inhibit the orphan nuclear receptor, NR2F6 (“Research Project”).
NR2F6 orphan nuclear receptor cell lines will be provided by Regen.
NPC and LOPAC compound libraries will be used to screen this receptor at NCATS.
Inventions made in the course of the Research Project will be owned by the Party employing the inventor or inventors. Inventions that are invented jointly by employees of both Parties will be owned jointly.
The Parties, moreover, agree to enter into an inter-institutional agreement with respect to joint inventions, which shall authorize Regen to have primary control and responsibility for any patenting and commercialization activities and shall be negotiated in good faith based on the respective parties’ contributions to each Joint Invention.
The term of this Agreement is for 3 years from December 16, 2015. This Agreement may be extended as mutually agreed by the Parties. This Agreement may be terminated upon thirty days written notice by the terminating Party to the other Party.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
Item 10.1 Agreement
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: December 16, 2015 By: /s/ David Koos
David Koos
Chief Executive Officer
Regen BioPharma Inks Deal With NCATS An Agency Of The National Institutes Of Health (NIH) US Govt! smile
We told you be patient with $RGBP that bigger things were coming - Well this week that day has Finally Come! smile
RGBP Announced the FDA Cleared HemaXellerate and the Initiation of and for Human/Patient Clinical Trials. smile
RGBP Partners with the US Government or a Branch thereof, NCATS/NIH, this is Big !!!! This company is going somewhere and is either going to be a Prime Candidate for a Merger or Buyout by Bigger Pharma or they will become the Leader in New Stem Cell Drugs and Treatments for many different disorders, diseases and life threatening illnesses. smile
http://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/4642986-otcbb-rgbp-regen-biopharma-inks-deal-with-ncats-an-agency-of-the-national-institutes-of-health-nih-us-govt
Regen BioPharma Inks Deal With NCATS An Agency Of The National Institutes Of Health (NIH) US Govt! smile
We told you be patient with $RGBP that bigger things were coming - Well this week that day has Finally Come! smile
RGBP Announced the FDA Cleared HemaXellerate and the Initiation of and for Human/Patient Clinical Trials. smile
RGBP Partners with the US Government or a Branch thereof, NCATS/NIH, this is Big !!!! This company is going somewhere and is either going to be a Prime Candidate for a Merger or Buyout by Bigger Pharma or they will become the Leader in New Stem Cell Drugs and Treatments for many different disorders, diseases and life threatening illnesses. smile
http://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/4642986-otcbb-rgbp-regen-biopharma-inks-deal-with-ncats-an-agency-of-the-national-institutes-of-health-nih-us-govt
Regen Biopharma, Inc. (PC) (RGBP)
http://ih.advfn.com/p.php?pid=nmona&article=69735998
Item 1.01 Entry Into A Material Definitive Agreement
On December 15, 2015 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services , pursuant to the following terms and conditions:
Regen and NCATS shall collaborate to screen for small molecule compounds that activate or inhibit the orphan nuclear receptor, NR2F6 (“Research Project”).
NR2F6 orphan nuclear receptor cell lines will be provided by Regen.
NPC and LOPAC compound libraries will be used to screen this receptor at NCATS.
Inventions made in the course of the Research Project will be owned by the Party employing the inventor or inventors. Inventions that are invented jointly by employees of both Parties will be owned jointly.
The Parties, moreover, agree to enter into an inter-institutional agreement with respect to joint inventions, which shall authorize Regen to have primary control and responsibility for any patenting and commercialization activities and shall be negotiated in good faith based on the respective parties’ contributions to each Joint Invention.
The term of this Agreement is for 3 years from December 16, 2015. This Agreement may be extended as mutually agreed by the Parties. This Agreement may be terminated upon thirty days written notice by the terminating Party to the other Party.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
Item 10.1 Agreement
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: December 16, 2015 By: /s/ David Koos
David Koos
Chief Executive Officer
NEW4, wonder if that divined will be for Hema spin off?
Month 18-24: Exit:
It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.
SO will we see trips or news first?
I'd like to see a PR/8K of financing with a dollar figure and then a PR that the dividend share will ipo on a big board
Another free dividend or our existing to start trading?
We will be seeing trips next week for sure.
I believe that 18% sounds correct, it was about 30% when RGBP only had 80M share out.
So the final hurdle for big box stores was cleared a week ago. Hope Nate has customers in line waiting on this to be completed.
One has to ask, how can someone show up day after day to post about a stock they hate? It does Not make a lot of sense unless that person has a lot of time on their hands or IF that person has their own agenda. My guess is option B, as no intelligent person would waste that much time on something that doesn't have a benefit.
All IMO of course.
CEO refuses to act like a CEO
Oh I didnt think he was going to provide it. However those posts only intimidate the newbies here, if figure my posts just offsets his.
Surf, I am sure you have links to support those claims. As usual we wont be holding our breath wait..
Exactly what is it you think they should be marketing? This is a development stage company, there is no product only several drugs in various stages of development.
I have the same issue with Scott, so I am afraid to lock in. If we get a big run, we could get screwed fast!
Think ill tweet him a link to this forum, then he can see first hand what we think of his leadership.
6:05 is an hour away, will today be 4 in a row?
I don't think he has given up, he is lost and needs so guidance in a bad way. That or he is using this as his personal ATM?
Herb I am with you, this is just baffling to me.
Great news 3 days in a row and price hasn't changed, it really is criminal.
Great post Laddyman
Really? I was unaware of that. Listen, I am not trying to come across like a basher, I just get very frustrated with poor follow through. I would rather be frustrated with a lack of news, than to get meaningless Twitter, FB & PRs.
I wont make another negative post here and will keep my frustration to myself.
Simple, I think he has over reached this time. He has had success in the past but he is simply over his head this time. He has too many projects he is working on, he is the sole employee. No support staff that we have heard of.
The Peter principle is a concept in management theory formulated by Laurence J. Peter in which the selection of a candidate for a position is based on the candidate's performance in their current role, rather than on abilities relevant to the intended role
I guess so, I know you like Brad but I have serious doubts about his ability to run a public co.
He needs to give us tangible and stop with this amateurish BS. I am starting to think there is a very good reason he has worked for so many companies. Its called the "peter principle".............
If this doesn't move us up.......
Wonder if we will see more news today?
NO you would think if they had this amazing app, there would be a link to Google Play or Itunes but nada, zilch!! Maybe even make a statement that it will be soon "available" in the following app stores.............
And another worthless FB post. Now the website references Drobbits & SWANTRY However is just mentions them, no links to the Drobbits sight, no link to download the app, doesn't event say what platform the app be for. For all Brads business experience, this sure seem to be handled like its armature hour.
Yup what Mikey said!!!!!
Ya but the blue ones are fun for fun!!
NEWS: Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Company Augments Intellectual Property Portfolio by Filing Broad Patent Claims Covering New Biochemical Validation Data
SAN DIEGO, California, December 16, 2015 /PRNewswire/ --
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
"We are optimistic that these initial positive data will lead the way forward into what we hope will be a new generation of immune stimulatory cancer drugs: Orally-available agents that will on the one hand unleash anticancer immune responses and on the other hand directly reprogram cancers rendering them less malignant," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "In parallel, we are continuing gene silencing studies with Santosh Kesari, M.D., Ph.D. in which we are precisely quantifying the correlation between inhibition of NR2F6 and immune stimulation. We believe that by using 2 independent approaches towards the same target, we will be in a position to accelerate clinical implementation and diversify our product pipeline." Dr. Santosh Kesari, a renowned neuro-oncologist who holds a doctorate in molecular biology, is with the John Wayne Cancer Institute at Providence Saint John's Health Center.
NR2F6 is a molecular switch known as an "orphan nuclear receptor", which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696B2 was assigned to Regen and covers means of screening small molecules such as the ones identified in the current patent filing.
"From a patient perspective, development of a 'checkpoint inhibitor pill' offers numerous potential advantages to currently utilized checkpoint inhibitors in terms of cost, lack of need for injections, and potentially better control of the drug's activities," said David Koos, Ph.D., Chairman and CEO of Regen.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
The Dorsee Company
Debra Dorsee
+1-(858)-229-6082
Debbie@thedorseecompany.com
http://www.regenbiopharma.com and
http://www.regenbiopharmainc.com
david.koos@regenbiopharma.com
Twitter: Regen BioPharma News:
https://twitter.com/KoosRegen
SOURCE Regen BioPharma Inc.
NEWS: Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Company Augments Intellectual Property Portfolio by Filing Broad Patent Claims Covering New Biochemical Validation Data
SAN DIEGO, California, December 16, 2015 /PRNewswire/ --
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
"We are optimistic that these initial positive data will lead the way forward into what we hope will be a new generation of immune stimulatory cancer drugs: Orally-available agents that will on the one hand unleash anticancer immune responses and on the other hand directly reprogram cancers rendering them less malignant," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "In parallel, we are continuing gene silencing studies with Santosh Kesari, M.D., Ph.D. in which we are precisely quantifying the correlation between inhibition of NR2F6 and immune stimulation. We believe that by using 2 independent approaches towards the same target, we will be in a position to accelerate clinical implementation and diversify our product pipeline." Dr. Santosh Kesari, a renowned neuro-oncologist who holds a doctorate in molecular biology, is with the John Wayne Cancer Institute at Providence Saint John's Health Center.
NR2F6 is a molecular switch known as an "orphan nuclear receptor", which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696B2 was assigned to Regen and covers means of screening small molecules such as the ones identified in the current patent filing.
"From a patient perspective, development of a 'checkpoint inhibitor pill' offers numerous potential advantages to currently utilized checkpoint inhibitors in terms of cost, lack of need for injections, and potentially better control of the drug's activities," said David Koos, Ph.D., Chairman and CEO of Regen.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
The Dorsee Company
Debra Dorsee
+1-(858)-229-6082
Debbie@thedorseecompany.com
http://www.regenbiopharma.com and
http://www.regenbiopharmainc.com
david.koos@regenbiopharma.com
Twitter: Regen BioPharma News:
https://twitter.com/KoosRegen
SOURCE Regen BioPharma Inc.
NEW you keep mentioning dividends, are you referring to another one for shareholders or our existing one starting to trade.
Keep it coming Koos!!
dCellVax should be on deck. First assessment should be due anytime.
June 10, 2015 /PRNewswire/ --
Regen BioPharma, Inc. (OTCBB: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma, Inc.'s planned Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 mont
See this post from L&L on the RGBP board, they openly stated they have been in contact with the big boys.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119071490
Pipeline is getting extensive http://www.regenbiopharmainc.com/product-pipeline.html